Obagi is best known for its dermatologist-dispensed skin care, but the brand is now making moves into the injectable category with the FDA approval of Saypha MagIQ, its first hyaluronic acid filler, set to launch in the U.S. in 2026.
According to the brand, Saypha MagIQ will be the first in the Obagi saypha line to debut in the U.S., with additional fillers such as Saypha ChIQ currently pending FDA review. In the U.S. clinical trial of 270 patients with a 48-week follow-up, the Saypha MagIQ demonstrated both safety and consistent, natural-looking results.
Saypha fillers are developed by Croma-Pharma, a family-owned company based in Austria. Products like Saypha Volume, Saypha Filler and Saypha Rich, are already widely used in Europe and other international markets.
For Obagi, the move into injectables allows the brand to offer a more complete package to patients in regard to their aesthetic choices. “This allows us to serve both providers and patients more completely,” Waldencast CEO Michel Brousset said in a statement earlier this year. “It’s about creating a more integrated approach to beauty and skin health.”
The launch would mark Obagi’s official entry into the U.S. filler market, joining established players like Allergan (Juvéderm), Galderma (Restylane), Revance (RHA Collection) and Evolus (Evolys). More details on the U.S. launch and availability are expected now that Saypha MagIQ has attained FDA approval.
